Ototoxic effects of carboplatin in organotypic cultures in chinchillas and rats

Journal of Otology

Volumn 7, Issue 2, 2012, Pages 92-102

  Dalian, Ding ^a,b   Haiyan, Jiang ^a   Yong, Fu ^a   SALVI, Richard ^a   SOMEYA, Shinichi ^a   TANOKURA, Masaru ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Carboplatin; organotypic culture; ototoxicity

Indexed keywords

EID: 84984587355     PISSN: None     EISSN: 16722930     Source Type: Journal    
DOI: 10.1016/S1672-2930(12)50023-1     Document Type: Article

References (142)

1. Calvert, A.H., Harland, S.J., Mewell, D.R., et al. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12 Suppl A (1985), 51–57.
2. Calvert, A.H., Harland, S.J., Newell, D.R., et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:3 (1982), 140–147.
3. Harland, S.J., Newell, D.R., Siddik, Z.H., et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44:4 (1984), 1693–1697.
4. Woloschuk, D.M., Pruemer, J.M., Cluxton, R.J., Carboplatin: a new cisplatin analog. Drug Intell Clin Pharm 22:11 (1988), 843–849.
5. McKeage, M.J., Comparative adverse effect profiles of platinum drugs. Drug Saf 13:4 (1995), 228–244.
6. Watanabe, K.C., Jinnouchi, K., Hess, A., et al. Carboplatin induces less apoptosis in the cochlea of guinea pigs than cisplatin. Chemotherapy 48:2 (2002), 82–87.
7. Canetta, R., The development and characteristics of carboplatin, a second generation platinum compound. Lectures and Symposia 14th Int. Cancer Congress, Budapest(9), 1986, 19–26.
8. van Hennik, M.B., van der Vijgh, W.J., Klein, I., et al. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 47:23 (1987), 6297–6301.
9. Kennedy, I.C., Fitzharris, B.M., Colls, B.M., et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol 26:3 (1990), 232–234.
10. Macdonald, M.R., Harrison, R.V., Wake, M., et al. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 23:3 (1994), 151–159.
11. Parsons, S.K., Neault, M.W., Lehmann, L.E., et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:7 (1998), 669–674.
12. Lockwood, D.S., Ding, D.L., Wang, J., et al. D-Methionine attenuates inner hair cell loss in carboplatin-treated chinchillas. Audiol Neurootol 5:5 (2000), 263–266.
13. Montaguti, M., Brandolini, C., Ferri, G.G., et al. Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital 22:1 (2002), 14–18.
14. Simon, T., Hero, B., Dupuis, W., et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 214:4 (2002), 149–152.
15. Dittrich, Ch., Sevelda, P., Salzer, H., et al. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer 39:8 (2003), 1129–1140.
16. Kanat, O., Evrensel, T., Baran, I., et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol 20:3 (2003), 237–245.
17. Smits, C., Swen, S.J., Theo Goverts, S., et al. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 42:4 (2006), 492–500.
18. Dean, J.B., Hayashi, S.S., Albert, C.M., et al. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 30:2 (2008), 130–134.
19. Fouladi, M., Gururangan, S., Moghrabi, A., et al. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 115:14 (2009), 3243–3253.
20. Grewal, S., Merchant, T., Reymond, R., et al. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 125:4 (2010), e938–e950.
21. Musial-Bright, L., Fengler, R., Henze, G., et al. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 27:3 (2011), 407–413.
22. Qaddoumi, I., Bass, J.K., Wu, J., et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 10:30 (2012), 1034–1041.
23. Tange, R.A., Dreschler, W.A., van der Hulst, R.J., The importance of high-tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol 242:1 (1985), 77–81.
24. Forastiere, A.A., Takasugi, B.J., Baker, S.R., et al. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 19:2 (1987), 155–158.
25. Gore, M.E., Calvert, A.H., Smith, L.E., High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol 23:9 (1987), 1391–1397.
26. van der Hulst, R.J., Dreschler, W.A., Urbanus, N.A., High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 97:2 Pt 1 (1988), 133–137.
27. Shea, T.C., Flaherty, M., Elias, A., et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:5 (1989), 651–661.
28. Wagstaff, A.J., Ward, A., Benfield, P., et al. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37:2 (1989), 162–190.
29. Kimura, S., Nakajima, Y., Hasegawa, S., et al. Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II–special reference to morphological changes. Nihon Hinyokika Gakkai Zasshi 80:4 (1989), 517–525.
30. Neuwelt, E.A., Brummett, R.E., Remsen, L.G., et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 56:4 (1996), 706–709.
31. Husain, K., Whitworth, C., Somani, S.M., et al. Carboplatin-induced oxidative stress in rat cochlea. Hear Res 159:1–2 (2001), 14–22.
32. Emerich, D.F., Winn, SR. Bartus RT. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats. Cell Transplant 11:1 (2002), 47–54.
33. Husain, K., Whitworth, C., Hazelrigg, S., et al. Carboplatin-in-duced oxidative injury in rat inferior colliculus. Int J Toxicol 22:5 (2003), 335–342.
34. Okur, E., Kilinc, M., Yildirim, I., et al. Effect of N-acetylcysteine on carboplatin-induced ototoxicity and nitric oxide levels in a rat model. Laryngoscope 117:12 (2007), 2183–2186.
35. Esteban-Fernandez, D., Verdaguer, J.M., Ramirez-Camacho, R., et al. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol 32:2 (2008), 140–146.
36. Schweitzer, V.G., Rarey, K.E., Dolan, D.F., et al. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 94:4 (1986), 458–470.
37. Saito, T., Saito, H., Saito, K., et al. Ototoxicity of carboplatin in guinea pigs. Auris Nasus Larynx 16:1 (1989), 13–21.
38. Taudy, M., Syka, J., Popelar, J., et al. Carboplatin and cisplatin ototoxicity in guinea pigs. Audiology 31:5 (1992), 293–299.
39. Delb, W., Feilen, S., Koch, A., et al. Comparative studies of the ototoxicity of cisplatin and carboplatin. Laryngorhinootologie 72:1 (1993), 24–27.
40. Thomas, J.P., Lautermann, J., Liedert, B., et al. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Pharmacol 70:1 (2006), 23–29.
41. Pochop, P., Darsova, D., Kukacka, J., et al. Intravitreal carboplatin concentration and area under concentration versus time curve after intravitreal and periocular delivery. Eur J Ophthalmol 20:4 (2010), 745–751.
42. Carey, J.P., Cooper, T., Jallo, G.I., et al. Ototoxicity of carboplatin delivered locally in a monkey brainstem. Int J Toxicol 24:6 (2005), 443–449.
43. Schurig, J.E., Schlein, A., Florczyk, A.P., et al. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents. Exp Hematol 13:Suppl 16 (1985), 101–105.
44. Shimoyama, Y., Kubota, T., Inoue, S., et al. Antitumor activity of cisplatin and carboplatin against human tumor xenografts serially transplanted into nude mice–with special reference to gastric carcinomas. Gan To Kagaku Ryoho 14:9 (1987), 2682–2687.
45. Kawano, S., Kohmura, H., Ohta, S., et al. Antigenicity study of carboplatin in guinea pigs and mice. J Toxicol Sci 13:Suppl 2 (1988), 1–21.
46. Raynaud, F.I., Boxall, F.E., Goddard, P.M., et al. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 11:3 (1997), 2063–2074.
47. Spankuch, B., Heim, S., Kurunci-Csacsko, E., et al. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 66:11 (2006), 5836–5846.
48. Vasin, M.V., Ushakov, I.B., Kovtun, V.Y., et al. Effect of radioprotector indralin on carboplatinum hemotoxicity. Bull Exp Biol Med 141:4 (2006), 437–439.
49. Chiu, L.L., Cunningham, L.L., Raible, D.W., et al. Using the zebrafish lateral line to screen for ototoxicity. J Assoc Res Otolaryngol 9:2 (2008), 178–190.
50. Ding, D., Salvi, R., Review of cellular changes in the cochlea due to aminoglycoside antibiotics. The Volta Review 105:3 (2005), 407–438.
51. Ding, D., Jiang, H., Wang, P., et al. Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res 226:1–2 (2007), 129–139.
52. Ding, D., Jiang, H., Salvi, R.J., Mechanisms of rapid sensory hair-cell death following co-administration of gentamicin and ethacrynic acid. Hear Res 259:1–2 (2010), 16–23.
53. Ding, D., Allman, A., Sh, Yin, et al. Cisplatin ototoxicity. Nova Science Publishers, Inc. Chapter 2(Hearing Loss Classification, Causes and Treatment), 2011, 39–63.
54. Hatzopoulos, S., Petruccelli, J., Laurell, G., et al. Electrophysiological findings in the Sprague-Dawley rat induced by moderate-dose carboplatin. Hear Res 182:1–2 (2003), 48–55.
55. Husain, K., Whitworth, C., Somani, S.M., et al. Partial protection by lipoic acid against carboplantin-induced ototoxicity in rats. Biomed Environ Sci 18:3 (2005), 198–206.
56. Wake, M., Takeno, S., Ibrahim, D., et al. Carboplatin ototoxicity: an animal model. J Laryngol Otol 107:7 (1993), 585–589.
57. Takeno, S., Harrison, R.V., Ibrahim, D., et al. Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res 75:1–2 (1994), 93–102.
58. Takeno, S., Harrison, R.V., Mount, R.J., et al. Induction of selective inner hair cell damage by carboplatin. Scanning Microsc 8:1 (1994), 97–106.
59. Wake, M., Takeno, S., Ibrahim, D., et al. Selective inner hair cell ototoxicity induced by carboplatin. Laryngoscope 104:4 (1994), 488–493.
60. Ding, D., Wang, J., Salvi, R.J., et al. Early damage in the chinchilla vestibular sensory epithelium from carboplatin. Audiol Neurootol 2:3 (1997), 155–167.
61. Hofstetter, P., Ding, D., Powers, N., et al. Quantitative relationship of carboplatin dose to magnitude of inner and outer hair cell loss and the reduction in distortion product otoacoustic emission amplitude in chinchillas. Hear Res 112:1–2 (1997), 199–215.
62. Hofstetter, P., Ding, D., Salvi, R.J., Magnitude and pattern of inner and outer hair cell loss in chinchilla as a function of carboplatin dose. Audiology 36:6 (1997), 301–311.
63. Hofstetter, P., Ding, D., Salvi, R.J., Induction of spontaneous otoacoustic emissions in chinchillas from carboplatin-induced inner hair cell loss. Hear Res 150:1–2 (2000), 132–136.
64. Wang, J., Ding, D., Salvi, R.J., Carboplatin-induced early cochlear lesion in chinchillas. Hear Res 181:1–2 (2003), 65–72.
65. Wang, J., Powers, N.L., Hofstetter, P., et al. Effects of selective inner hair cell loss on auditory nerve fiber threshold, tuning and spontaneous and driven discharge rate. Hear Res 107:1–2 (1997), 67–82.
66. Ding, D., Wang, J., Salvi, R.J., et al. Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann N Y Acad Sci 884 (1999), 152–170.
67. Salvi, R.J., Wang, J., Ding, D., et al. Auditory deprivation of the central auditory system resulting from selective inner hair cell loss: animal model of auditory neuropathy. Scand Audiol Suppl 51 (1999), 1–12.
68. Spicer, S.S., Salvi, R.J., Schulte, B.A., Ablation of inner hair cells by carboplatin alters cells in the medial K(+) flow route and disrupts tectorial membrane. Hear Res 136:1–2 (1999), 139–150.
69. Salvi, R.J., Wang, J., Ding, D., Auditory plasticity and hyperactivity following cochlear damage. Hear Res 147:1–2 (2000), 261–274.
70. Spicer, S.S., Salvi, R.J., Schulte, B.A., Ultrastructural changes in the spiral limbus associated with carboplatin-induced ablation of inner hair cells. Cell Tissue Res 302:1 (2000), 1–10.
71. Ding, D., Jiang, H., Wang, J., et al. Carboplatin-induced vestibular damage: Quantitative measurement of type I hair cell loss and ganglion cell loss. Journal of Audiology and Speech Pathology 10:3 (2002), 170–173.
72. Bauer, C.A., Brozoski, T.J., Cochlear structure and function after round window application of ototoxins. Hear Res 201:1–2 (2005), 121–131.
73. Yang, J., Ding, D., Wu, H., et al. Carboplatin-induced injury patterns of inner hair cells missing in chinchilla cochlea. Lin Chuang Er Bi Yan Hou Ke Za Zhi 19:10 (2005), 457–460.
74. Ding, D., Qi, W., Qu, Y., et al. Carboplatin and its ototoxicity. Chinese Journal of Otology 6:2 (2008), 134–144.
75. Mount, R.J., Takeno, S., Wake, M., et al. Carboplatin ototoxicity in the chinchilla: lesions of the vestibular sensory epithelium. Acta Otolaryngol Suppl 519 (1995), 60–65.
76. Jiang, H., Ding, D., Salvi, R.J., Carboplatin induced cochlear hair cell lesion in organotypic cultures. Association for Research in Otolaryngology Abstract book, 193, 2006.
77. Jiang, H., Ding, D., Fu, Y., et al. Ototoxic effects of carboplatin in organotypic cultures in rats and chinchillas. Abstr Assoc Res Otolaryngol Abstract book, 245, 2010.
78. Moon, I.J., Kim, K.R., Chu, H.S., et al. N-acetylcysteine and N-nitroarginine methyl ester attenuate Carboplatin-induced ototoxicity in dissociated spiral ganglion neuron cultures. Clin Exp Otorhinolaryngol 4:1 (2011), 11–17.
79. Ding, D., Qi, W., Yu, D., et al. Ototoxic effects of mefloquine in cochlear organotypic cultures. Journal of Otology 4:2 (2009), 29–38.
80. Ding, D., Stracher, A., Salvi, R.J., Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hear Res 164:1–2 (2002), 115–126.
81. Ding, D., Roth, J., Salvi, R.J., Manganese is toxic to spiral ganglion neurons and hair cells in vitro. Neurotoxicology 32:2 (2011), 233–241.
82. Ding, D., Allman, B.L., Salvi, R.J., Review: Ototoxic Characteristics of Platinum Antitumor Drugs. Anat Rec (Hoboken) 295 (2012), 1851–1867.
83. Ding, D., Fu, Y., Jiang, H., et al. Oxaliplatin ototoxicity in rat cochlear organotypic cultures. Abstr Assoc Res Otolaryngol Abstract book, 247, 2010.
84. Ding, D., He, J., Allman, B.L., et al. Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res 282:1–2 (2011), 196–203.
85. Ding, D., Qi, W., Zhang, M., et al. Cisplatin and its ototoxicity. Chinese Journal of Otology 6:2 (2008), 125–133.
86. McFadden, S.L., Kasper, C., Ostrowski, J., et al. Effects of inner hair cell loss on inferior colliculus evoked potential thresholds, amplitudes and forward masking functions in chinchillas. Hear Res 120:1–2 (1998), 121–132.
87. Ding, L., McFadden, S.L., Salvi, R.J., Calpain immunoreactivity and morphological damage in chinchilla inner ears after carboplatin. J Assoc Res Otolaryngol 3:1 (2002), 68–79.
88. Li, Y., Godfrey, D.A., Godfrey, M.A., et al. Effects of carboplatin on amino acid chemistry in chinchilla cochlear nucleus. Hear Res 165:1–2 (2002), 19–29.
89. Saito, T., Manabe, Y., Honda, N., et al. Semiquantitative analysis by scanning electron microscopy of cochlear hair cell damage by ototoxic drugs. Scanning Microsc 9:1 (1995), 271–280 discussion 280–271.
90. Ishida, S., Lee, J., Thiele, D.J., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:22 (2002), 14298–14302.
91. Lin, X., Okuda, T., Holzer, A., et al. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:5 (2002), 1154–1159.
92. Petris, M.J., Voskoboinik, I., Cater, M., et al. Copper-regulated trafficking of the Menkes disease copper ATPase is associated with formation of a phosphorylated catalytic intermediate. J Biol Chem 277:48 (2002), 46736–46742.
93. Guo, Y., Smith, K., Petris, M.J., Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. J Biol Chem 279:45 (2004), 46393–46399.
94. Holzer, A.K., Samimi, G., Katano, K., et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:4 (2004), 817–823.
95. Safaei, R., Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 234:1 (2006), 34–39.
96. Safaei, R., Howell, S.B., Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:1 (2005), 13–23.
97. Safaei, R., Otani, S., Larson, B.J., et al. Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol 73:2 (2008), 461–468.
98. Kuo, M.T., Chen, H.H., Song, I.S., et al. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 26:1 (2007), 71–83.
99. Owatari, S., Akune, S., Komastsu, M., et al. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 67:10 (2007), 4860–4868.
100. Yoshizawa, K., Nozaki, S., Kitahara, H., et al. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Oncol Rep 18:4 (2007), 987–991.
101. Zisowsky, J., Koegel, S., Layers, S., et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 73:2 (2007), 298–307.
102. He, J., Ding, D., Yu, D., et al. Modulation of copper transporters in protection against cisplatin-induced cochlear hair cell damage. Journal of Otology 6:2 (2011), 53–61.
103. Puig, S., Thiele, D.J., Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol 6:2 (2002), 171–180.
104. Ding, D., Jiang, H., MeFadden, S.L., et al. Ethacrynic acid is the key for opening of the blood-labyrinth barrier. Chinese Journal of Otology 1:2 (2004), 42–47.
105. Ding, D., Jiang, H., Salvi, R.J., Local application of copper sulfate protects cochlear hair cells against carboplatin in chinchillas. Abstr Assoc Res Otolaryngol Abstract book, 56, 2012.
106. Ding, D., McFadden, S.L., Browne, R.W., et al. Late dosing with ethacrynic acid can reduce gentamicin concentration in perilymph and protect cochlear hair cells. Hear Res 185:1–2 (2003), 90–96.
107. Ding, D., McFadden, S.L., Woo, J.M., et al. Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear Res 173:1–2 (2002), 1–9.
108. Ding, D., Wu, X., Liu, H., et al. Ototoxicity and neurotoxicity of nedaplatin in cochlear organotypic cultures. Abstr Assoc Res Otolaryngol Abstract book, 208, 2011.
109. Clerici, W.J., Hensley, K., DiMartino, D.L., et al. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 98:1–2 (1996), 116–124.
110. Kopke, R.D., Liu, W., Gabaizadeh, R., et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 18:5 (1997), 559–571.
111. Dehne, N., Lautermann, J., Petrat, F., et al. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 174:1 (2001), 27–34.
112. Li, G., Liu, W., Frenz, D., et al. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS. Neurotoxicology 27:1 (2006), 22–30.
113. Jamesdaniel, S., Coling, D., Hinduja, S., et al. Cisplatin-induced ototoxicity is mediated by nitroxidative modification of cochlear proteins characterized by nitration of Lmo4. J Biol Chem 287:22 (2012), 18674–18686.
114. Ravi, R., Somani, S.M., Rybak, L.P., Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 76:6 (1995), 386–394.
115. Campbell, K.C., Rybak, R.P., Rybak, L.P., et al. D-methionine protects against cisplatin damage to the stria vascularis. Hear Res 138:1–2 (1999), 13–28.
116. Kemp, G., Rose, P., Lurain, J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:7 (1996), 2101–2112.
117. Rybak, L.P., Husain, K., Whitworth, C., et al. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci 47:2 (1999), 195–202.
118. Li, G., Frenz, D.A., Brahmblatt, S., et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 22:2 (2001), 163–176.
119. Aamdal, S., Fodstad, O., Pihl, A., et al. Some procedures to reduce cis-platinum toxicity reduce antitumour activity. Cancer Treat Rev 14:3–4 (1987), 389–395.
120. Basinger, M.A., Jones, M.M., Holscher, M.A., et al. L-methionine antagonism of cis-platinum nephrotoxicity. Toxicol Appl Pharmacol 103:1 (1990), 1–15.
121. Liu, W., Staecker, H., Stupak, H., et al. Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. Neuroreport 9:11 (1998), 2609–2614.
122. Lau, A.H., Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 56:4 (1999), 1295–1298.
123. Alam, S.A., Ikeda, K., Oshima, T., et al. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res 141:1–2 (2000), 28–38.
124. Gonzalez, V.M., Fuertes, M.A., Alonso, C., et al. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 59:4 (2001), 657–663.
125. Park, S.A., Park, H.J., Lee, B.I., et al. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 93:1 (2001), 18–26.
126. Hershberger, P.A., McGuire, T.F., Yu, W.D., et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 1:10 (2002), 821–829.
127. Lee, J.E., Nakagawa, T., Kim, T.S., et al. A novel model for rapid induction of apoptosis in spiral ganglions of mice. Laryngoscope 113:6 (2003), 994–999.
128. Xu, H.J., Huang, W.N., Cisplatin-induced apoptotic cell death in spiral ganglion and organ of Corti of mongolian gerbil cochlear. Zhonghua Er Bi Yan Hou Ke Za Zhi 38:2 (2003), 98–100.
129. Zhang, M., Liu, W., Ding, D., et al. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 120:1 (2003), 191–205.
130. Arany, I., Megyesi, J.K., Kaneto, H., et al. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287:3 (2004), F543–F549.
131. Marklund, L., Andersson, B., Behnam-Motlagh, P., et al. Cellular potassium ion deprivation enhances apoptosis induced by cisplatin. Basic Clin Pharmacol Toxicol 94:5 (2004), 245–251.
132. Kim, Y.K., Kim, H.J., Kwon, C.H., et al. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25:5 (2005), 374–382.
133. Yu, F., Megyesi, J., Safirstein, R.L., et al. Identification of the functional domain of p21(WAF1/CIP1) that protects cells from cisplatin cytotoxicity. Am J Physiol Renal Physiol 289:3 (2005), F514–F520.
134. Jiang, M., Wei, Q., Wang, J., et al. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25:29 (2006), 4056–4066.
135. Jirsova, K., Mandys, V., Gispen, W.H., et al. Cisplatin-induced apoptosis in cultures of human Schwann cells. Neurosci Lett 392:1–2 (2006), 22–26.
136. Ding, D., Wang, P., Jiang, H., et al. Gene expression in cisplatin ototoxicity and protection with p53 inhibitor. Chinese Journal of Otology 4:2 (2009), 15–24.
137. Xu, L., Kong, D., Zhu, L., et al. Suppression of IP3-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. Mol Cell Biochem 295:1–2 (2007), 153–165.
138. Yang, C., Kaushal, V., Shah, S.V., et al. Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am J Physiol Renal Physiol 292:6 (2007), F1710–F1717.
139. Yano, T., Itoh, Y., Matsuo, M., et al. Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis 12:10 (2007), 1901–1909.
140. Gao, W.Q., Dybdal, N., Shinsky, N., et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 38:1 (1995), 30–37.
141. Zheng, J.L., Gao, W.Q., Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures. Eur J Neurosci 8:9 (1996), 1897–1905.
142. Zheng, J.L., Stewart, R.R., Gao, W.Q., Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci 15:7 Pt 2 (1995), 5079–5087.